Literature DB >> 22664430

The non-association of Panton-Valentine leukocidin and mecA genes in the genome of Staphylococcus aureus from hospitals in South Western Nigeria.

O A Terry Alli1, D O Ogbolu, J O Mustapha, R Akinbami, A O Ajayi.   

Abstract

PURPOSE: Virulence genes play important roles in pathogenesis of infections caused by S. aureus. The aim of this study was to determine the prevalence of PVL, eta and mecA genes in S. aureus isolated from patients in South-Western Nigeria.
MATERIALS AND METHODS: In this study, a total of 116 S. aureus isolates from the clinical specimens submitted to laboratories in tertiary hospitals in the South Western Nigeria were used. Antibiotic susceptibility test was carried out to determine the susceptibility pattern of the isolates using multiple antibiotics disc. Minimum inhibitory concentration (MIC) was also carried out to determine the degree of resistant of the isolates to methicillin. PCR was used to screen for the presence of PVL, eta, and mecAgenes.
RESULTS: mecA gene was detected in 48 (41.4%) of 116 strains of S. aureus. The MIC 50 and MIC 90 for mecA negative strains were 1 and 8 μg/ml, respectively while the MIC 50 and MIC 90 for mecA positive were >256 μg/ml. Twenty eight (24.1%) of 116 isolates were PVL gene positive with none of them mecA+. The prevalence of community acquired MRSA (CA-MRSA) was estimated to be 6.9% using molecular techniques. No localization of mecA gene and PVL gene on the genome of the entire S. aureus strains studied. Site of isolation of organism /specimen type was found to be associated with the prevalence of PVL+ and mecA+ S. aureus (P< 0.01).
CONCLUSION: This study concludes that the PVL+ MRSA is rare and the prevalence of CA-MRSA is low in South-Western, Nigeria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664430     DOI: 10.4103/0255-0857.96675

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  7 in total

1.  High frequency of SCCmec type IV and multidrug-resistant SCCmec type I among hospital acquired methicillin-resistant Staphylococcus aureus isolates in Birjand Imam Reza Hospital, Iran.

Authors:  Toktam Sadeghi Moghaddam; Mohammad Hasan Namaei; Davoud Afshar; Masoud Yousefi
Journal:  Iran J Microbiol       Date:  2022-02

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus case studies.

Authors:  Madeleine G Sowash; Anne-Catrin Uhlemann
Journal:  Methods Mol Biol       Date:  2014

3.  The Association of Panton-Valentine leukocidin and mecA Genes in Methicillin-Resistant Staphylococcus aureus Isolates From Patients Referred to Educational Hospitals in Ahvaz, Iran.

Authors:  Hossein Motamedi; Seyyed Soheil Rahmat Abadi; Seyyed Mojtaba Moosavian; Maryam Torabi
Journal:  Jundishapur J Microbiol       Date:  2015-08-27       Impact factor: 0.747

Review 4.  Molecular epidemiology of Methicillin-resistant Staphylococcus aureus in Africa: a systematic review.

Authors:  Shima M Abdulgader; Adebayo O Shittu; Mark P Nicol; Mamadou Kaba
Journal:  Front Microbiol       Date:  2015-04-30       Impact factor: 5.640

5.  NASAL CARRIAGE OF MULTI-DRUG RESISTANT PANTON VALENTINE LEUKOCIDIN POSITIVE STAPHYLOCOCCUS AUREUS IN HEALTHY INDIVIDUALS OF TUDUN-WADA, GOMBE STATE, NIGERIA.

Authors:  Adebola Onanuga; Ocholi Jonathan Adamu; Babatunde Odetoyin; Jabir Adamu Hamza
Journal:  Afr J Infect Dis       Date:  2020-12-14

6.  Antibiotic Susceptibility of Staphylococcus aureus and Streptococcus pneumoniae Isolates from the Nasopharynx of Febrile Children under 5 Years in Nanoro, Burkina Faso.

Authors:  Massa Dit Achille Bonko; Palpouguini Lompo; Marc Christian Tahita; Francois Kiemde; Ibrahima Karama; Athanase M Somé; Petra F Mens; Sandra Menting; Halidou Tinto; Henk D F H Schallig
Journal:  Antibiotics (Basel)       Date:  2021-04-15

7.  MRSA in Africa: filling the global map of antimicrobial resistance.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; John Leptidis; Ioanna P Korbila
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.